Signet Financial Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-425
Closed -$48K 1358
2021
Q4
$48K Buy
+425
New +$51.3K 0.01% 489

Other funds holding XBI

Signet Financial Management's XBI Position: Q1 2022 in Review

Signet Financial Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 425 shares — an estimated $48K sold.

Signet Financial Management first reported a position in XBI in Q4 2021 and held it in 1 quarter. The position peaked at $48K in Q4 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

  • Signet Financial Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
  • Signet Financial Management sold 425 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $48K.
  • Signet Financial Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 1 quarter.
  • Signet Financial Management's State Street SPDR S&P Biotech ETF position peaked at $48K in Q4 2021.
  • 703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Signet Financial Management's 13F filing for Q1 2022, filed 13 May 2022.